Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Drug Profile

IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology

Alternative Names: IM19 CAR-T cells; IM19-CAR-T-Cells-Beijing-Immunochina-Medical-Science-and-Technology; IM19CAR-T; IM19CAR-T-Beijing-Immunochina-Medical-Science-and-Technology

Latest Information Update: 22 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Immunochina Medical Science and Technology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Leukaemia
  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 22 Oct 2020 Phase I development for Non-Hodgkin's lymphoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) is still ongoing in China (NCT03344705)
  • 04 Jun 2020 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Recurrent) in China (IV) (NCT04440436)
  • 27 Sep 2019 Efficacy and safety data from phase I trial in Non-Hodgkin's lymphoma presented at 44th European Society for Medical Oncology Congress (ESMO-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top